JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report

被引:3
作者
Yhim, Ho-Young [1 ]
Kim, Hee Sun [4 ]
Sohn, Ji-Youn [1 ]
Song, Min-Ju [1 ]
Lee, Na-Ri [1 ,3 ]
Song, Eun-Kee [1 ,3 ]
Choi, Sam-Im [2 ]
Yim, Chang-Yeol [1 ,3 ]
Kwak, Jae-Yong [1 ,3 ]
机构
[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Jeonju 561712, South Korea
[2] Chonbuk Natl Univ, Sch Med, Dept Lab Med, Jeonju 561712, South Korea
[3] Chonbuk Natl Univ, Sch Med, Adv Res Canc Ctr, Jeonju 561712, South Korea
[4] Jeonbuk Sci Coll, Dept Nursing, Jeongeup 580712, South Korea
关键词
TYROSINE KINASE JAK2; CANCER INCIDENCE; MYELOID METAPLASIA; MUTATION; MEN;
D O I
10.1016/j.cancergencyto.2010.01.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [31] No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation
    Gau, Jyh-Pyng
    Chen, Chih-Cheng
    Chou, Yi-Sheng
    Liu, Chia-Jen
    Yu, Yuan-Bin
    Hsiao, Liang-Tsai
    Liu, Jin-Hwang
    Hsu, Hui-Chi
    Chiou, Tzeon-Jye
    Chen, Ro -Min
    Tzeng, Cheng-Hwai
    BLOOD CELLS MOLECULES AND DISEASES, 2015, 55 (01) : 36 - 39
  • [32] JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis: The Role of Bone Marrow Biopsy for the Diagnosis of Myeloproliferative Disease
    Allegra, Alessandro
    Alonci, Andrea
    Penna, Giuseppa
    D'Angelo, Arianna
    Rizzotti, Patricia
    Granata, Angela
    Musolino, Caterina
    ACTA HAEMATOLOGICA, 2009, 121 (04) : 218 - 220
  • [33] JAK2 V617F-Mutated Myeloproliferative Neoplasia Developing Five Years after Wild-Type JAK2 Acute Myeloid Leukemia: A Case Report
    Girsberger, Sabine
    Karow, Axel
    Lundberg, Pontus
    Dirnhofer, Stephan
    Lehmann, Thomas
    Passweg, Jakob R.
    Tichelli, Andre
    Skoda, Radek
    Rovo, Alicia
    ACTA HAEMATOLOGICA, 2013, 129 (01) : 23 - 25
  • [34] Absence of JAK2 V617F mutation in thalassemia intermedia patients
    Taher, Ali
    Shammaa, Dina
    Bazarbachi, Ali
    Itani, Doha
    Zaatari, Ghazi
    Greige, Layal
    Otrock, Zaher K.
    Mahfouz, Rami A. R.
    MOLECULAR BIOLOGY REPORTS, 2009, 36 (06) : 1555 - 1557
  • [35] Absence of JAK2 V617F mutation in thalassemia intermedia patients
    Ali Taher
    Dina Shammaa
    Ali Bazarbachi
    Doha Itani
    Ghazi Zaatari
    Layal Greige
    Zaher K. Otrock
    Rami A. R. Mahfouz
    Molecular Biology Reports, 2009, 36 : 1555 - 1557
  • [36] International external quality assurance of JAK2 V617F quantification
    Asp, Julia
    Skov, Vibe
    Bellosillo, Beatriz
    Kristensen, Thomas
    Lippert, Eric
    Dicker, Frank
    Schwarz, Jiri
    Wojtaszewska, Marzena
    Palmqvist, Lars
    Akiki, Susanna
    Aggerholm, Anni
    Andersen, Morten Tolstrup
    Girodon, Francois
    Kjaer, Lasse
    Leibundgut, Elisabeth Oppliger
    Pancrazzi, Alessandro
    Vorland, Marta
    Andrikovics, Hajnalka
    Kralovics, Robert
    Cassinat, Bruno
    Coucelo, Margarida
    Eftimov, Aleksandar
    Haslam, Karl
    Kusec, Rajko
    Link-Lenczowska, Dorota
    Lode, Laurence
    Matiakowska, Karolina
    Naguib, Dina
    Navaglia, Filippo
    Novotny, Guy Wayne
    Percy, Melanie J.
    Sudarikov, Andrey
    Hermouet, Sylvie
    Pallisgaard, Niels
    ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1111 - 1118
  • [37] JAK2 V617F MUTATION SCANNING IN PATIENTS WITH ADRENAL INCIDENTALOMA
    Ekinci, F.
    Soyaltin, U. E.
    Kutbay, Y. B.
    Yasar, H. Y.
    Yildirim, T. Demirci
    Akar, H.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2017, 13 (02) : 150 - 153
  • [38] The V617F mutation of JAK2 is very uncommon in patients with thrombosis
    Remacha, Angel F.
    Estivill, Camino
    Pilar Sarda, M.
    Mateo, Jose
    Carles Souto, Joan
    Canals, Carme
    Nomdedeu, Josep
    Fontcuberta, Jordi
    HAEMATOLOGICA, 2007, 92 (02) : 285 - 286
  • [39] Clinical relevance of JAK2 (V617F) mutant allele burden
    Passamonti, Francesco
    Rumi, Elisa
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 7 - 10
  • [40] Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Edahiro, Yoko
    Sunami, Yoshitaka
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Sato, Eriko
    Ohsaka, Akimichi
    Komatsu, Norio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (02) : 148 - 153